Drs. Newhall and Gupta discuss how biologic therapies are transforming care for patients with multiple allergic diseases—such as asthma, atopic dermatitis, nasal polyps, food allergy, and eosinophilic esophagitis—while also making treatment decisions more complex. They explain how they choose among biologics like dupilumab, omalizumab, IL‑5 blockers, and TSLP inhibitors by focusing on biomarkers, age, comorbidities, and which condition most affects the patient’s quality of life.
Podden och tillhörande omslagsbild på den här sidan tillhör
PeerDirect. Innehållet i podden är skapat av PeerDirect och inte av,
eller tillsammans med, Poddtoppen.
